Careers: Join Our Team


Vice President, Clinical Pharmacology

Position Summary:


At Aditum Bio our mission is to give patients access to medicines that may not otherwise be developed. Co-founded by industry veterans Joe Jimenez and former CEO of Novartis and Mark Fishman, former President of the Novartis Institutes for Biomedical Research, we focus on the translational phase of medicine (Phase I and Phase II) to generate data that can support full clinical development, and eventual market launch, to reach patients in need.

We are currently seeking a Vice President of Clinical Pharmacology. This person will be responsible for hands on planning and execution of Aditum Bio companies’ nonclinical/translational programs, with focus on clinical pharmacology and DMPK/ADME. They will work in partnership with Aditum Bio’s Vice President of Nonclinical Development, Chief Medical Officer, Translational Medicine and in close collaboration with Aditum Bio’s portfolio company teams, strategic partners, and vendors.

Position Responsibilities:


Strategy and Planning: 

  • Close interface with Nonclinical Development and Aditum Bio Company cross-functional teams to support nonclinical and translational needs of multiple programs. 

  • Provide nonclinical DMPK/ADME expertise across multiple programs.

  • Ensure the integration of nonclinical and early clinical findings with planned clinical programs.

  • Execute plans in accordance with regulatory guidelines and expectations.

  • Partner with and maintain regular contact with key stakeholders including Program Management, Quality Assurance, Regulatory Affairs, CMC, Medical, Legal and Finance. 

Partner Collaborations: 


  • Manage Contract Research Organizations (CROs) and consultants for nonclinical pharmacology, toxicology and nonclinical ADME/PK in support of ongoing programs. 

  • Work with academic institutions and CROs to translate animal efficacy models for clinical programs.


Program Execution and Oversight:


  • Design, execute, analyze and interpret nonclinical development studies and data (nonclinical DMPK/ADME and beyond). 

  • Oversee the implementation of nonclinical programs, including delivery of reports and results in accordance with regulatory guidelines and program strategy. 

  • Provide project team updates and guidance to Aditum Bio companies on nonclinical matters.




  • PhD in scientific discipline (related to drug development).


  • Pharmaceutical/biotechnology industry experience (15+ years) specializing in nonclinical DMPK and developing small and large molecules for various indications.


  • Experience building and managing collaborations with other scientists, CROs, consultants, pharmaceutical partners and outside organizations.


  • Ability to be hands-on/independent contributor as well as oversee/manage nonclinical studies.


  • Desire to build a broad understanding of drug development as evidenced by contributions to INDs, regulatory interactions, NDAs, drug approvals and peer reviewed publications.


  • Strong data analysis skills and proficiency presenting data.


  • Ability to identify, prioritize and resolve critical issues; flexible and skilled at juggling multiple projects across different indications.


  • Strong track record in effectively working with colleagues and senior management on project teams.


  • Ability to manage timelines and understand interplay between impact, timing and budget of nonclinical studies and overall project goals.

Company Overview:


Aditum Bio is a new model of biotech venture capital uniquely positioned to rapidly translate scientific discoveries into innovative new medicines. Aditum brings together unmatched scientific and domain expertise, combined with operational capabilities. Our agile operating model enables rapid company formation, planning, and execution for a new model of drug development. We target clinic-ready therapies to help underserved patient populations, rapidly forming companies and staffing them with medical and scientific experts. Launched in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedical Research, Dr. Mark Fishman, Aditum currently manages a broad portfolio of clinical stage companies with multiple drug candidates entering Phase 2 clinical trials in 2022.

Aditum Bio provides equal employment opportunities to all employees and applicants for employment and prohibits discrimination and harassment of any type without regard to race, color, religion, age, sex, national origin, disability status, genetics, protected veteran status, sexual orientation, gender identity or expression, or any other characteristic protected by federal, state or local laws.